CLIOSS is committed in the clinical development and life-cycle management of compounds starting from phase I, First-Time-In-Man, to phase IV, including drug registration and extension of indications.
Based in Nerviano, CLIOSS operates internationally for biopharmaceutical companies, biotech and research IRCCS institutes, hospitals and universities, providing strategic consultancy and a full range of integrated services: from clinical research to study management, from regulatory activities to pharmacovigilance, from biostatistics & programming to quality assurance.
CLIOSS has developed strong partnerships with selected opinion leaders, researchers and institutions among the best known and appreciated in the world, becoming an Italian point of reference and excellence. This leading positioning is stabilized also for Clioss strategic capability in developing innovative medicines, with high quality standards and flexibility for business.
Thanks to a consolidated experience and development platforms today headed by NMS Group, CLIOSS has a particular specialization in clinical development in oncology and onco-hematology.